Adenosine deaminase: Difference between revisions
Sandcountry (talk | contribs) |
|||
Line 49: | Line 49: | ||
ADA2 is the predominant form present in human [[blood plasma]] and is increased in many diseases, particularly those associated with the immune system: for example [[rheumatoid arthritis]], [[psoriasis]] and [[sarcoidosis]]. The plasma AD2 isoform is also increased in most cancers. |
ADA2 is the predominant form present in human [[blood plasma]] and is increased in many diseases, particularly those associated with the immune system: for example [[rheumatoid arthritis]], [[psoriasis]] and [[sarcoidosis]]. The plasma AD2 isoform is also increased in most cancers. |
||
Total plasma ADA can be measured using [[high performance liquid chromatography]], enzymatic or colorimetric techniques. Perhaps the simplest system is the measurement of the [[ammonia]] released from adenosine when broken down to inosine. After incubation of plasma with a buffered solution of adenosine the ammonia is reacted with a [[Berthelot reagent]] to form a blue colour which is proportionate to the amount of enzyme activity. To measure ADA2, [[EHNA|erythro-9-(2-hydroxy-3-nonyl) adenine]] (EHNA) is |
Total plasma ADA can be measured using [[high performance liquid chromatography]], enzymatic or colorimetric techniques. Perhaps the simplest system is the measurement of the [[ammonia]] released from adenosine when broken down to inosine. After incubation of plasma with a buffered solution of adenosine the ammonia is reacted with a [[Berthelot reagent]] to form a blue colour which is proportionate to the amount of enzyme activity. To measure ADA2, [[EHNA|erythro-9-(2-hydroxy-3-nonyl) adenine]] (EHNA) is added prior to incubation so as to inhibit the enzymatic acivity of ADA1. It is the absence of ADA1 that causes SCID. |
||
==See also== |
==See also== |
Revision as of 14:10, 29 July 2007
adenosine deaminase | |||||||
---|---|---|---|---|---|---|---|
Identifiers | |||||||
Symbol | ADA | ||||||
NCBI gene | 100 | ||||||
HGNC | 186 | ||||||
OMIM | 608958 | ||||||
RefSeq | NM_000022 | ||||||
UniProt | P00813 | ||||||
Other data | |||||||
EC number | 3.5.4.4 | ||||||
Locus | Chr. 20 q13.12 | ||||||
|
Adenosine deaminase (also known as ADA) is an enzyme (EC 3.5.4.4)involved in purine metabolism. It is needed for the breakdown of adenosine from food and for the turnover of nucleic acids in tissues.
Reactions
ADA irreversibly deaminates adenosine, converting it to the related nucleoside inosine by the removal of an amino group.
-
Inosine (observe missing nitrogen in upper left)
Inosine can then be deribosylated (removed from ribose) by another enzyme called purine nucleoside phosphorylase (PNP), converting it to hypoxanthine.
Pathology
Mutations in the gene for adenosine deaminase causing it to not be expressed are one cause of severe combined immunodeficiency (SCID).
Mutations causing it to be overexpressed are one cause of hemolytic anemia.
There is some evidence that a different allelle (ADA2) may lead to autism.
Isoforms
There are 2 isoforms of ADA: ADA1 and ADA2.
- ADA1 is found in most body cells, particularly lymphocytes and macrophages, where it is present not only in the cytosol and nucleus but also as the ecto- form on the cell membrane attached to a protein called CD26.
- ADA2 was first identifed in human thymus. It was subsequently found in other tissues including the macrophage where it co-exists with ADA1. The two isoforms regulate the ratio of adenosine to deoxyadenosine potentiating the killing of parasites.
- An RNA-specific ADA also exists.
Clinical significance
ADA2 is the predominant form present in human blood plasma and is increased in many diseases, particularly those associated with the immune system: for example rheumatoid arthritis, psoriasis and sarcoidosis. The plasma AD2 isoform is also increased in most cancers.
Total plasma ADA can be measured using high performance liquid chromatography, enzymatic or colorimetric techniques. Perhaps the simplest system is the measurement of the ammonia released from adenosine when broken down to inosine. After incubation of plasma with a buffered solution of adenosine the ammonia is reacted with a Berthelot reagent to form a blue colour which is proportionate to the amount of enzyme activity. To measure ADA2, erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) is added prior to incubation so as to inhibit the enzymatic acivity of ADA1. It is the absence of ADA1 that causes SCID.